Symrise AG said a plan to sell its terpene ingredients division and a reduction in the value of its stake in a pet-care business will likely curtail earnings for this year.
Sign in to read the full article.
Sign in with Google
Symrise AG said a plan to sell its terpene ingredients division and a reduction in the value of its stake in a pet-care business will likely curtail earnings for this year.
Sign in to read the full article.
Sign in with Google